BridgeBio’s oncology spinoff swaps out CEOs as it seeks to accelerate KRAS work

BridgeBio Oncology Therapeutics executive chairman Neil Kumar (L) and new CEO Pedro Beltran April 22, 2026 01:40 PM EDTUpdated 03:44 PM People Bridge­Bio’s on­col­o­gy spin­off swaps out CEOs as it seeks to ac­cel­er­ate KRAS work Drew Armstrong Executive Editor Bridge­Bio On­col­o­gy Ther­a­peu­tics is re­plac­ing CEO Eli Wal­lace, putting its CSO Pe­dro Bel­tran in the role, and mak­ing board mem­ber Neil Ku­mar ex­ec­u­tive chair­man. The … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER